Abstract
Parkinson’s Disease (PD) is a frustrating condition characterized by motor and nonmotor deficits majorly caused by the loss of dopaminergic cells in the Substantia Nigra pars compacta (SNc) and destruction of the nigrostriatal pathway. Despite the very respectable advances in cutting-edge approaches for the treatment of PD, there exist numerous challenges that have incapacitated the definitive treatment of this disease. This review emphasized the development of various non-pharmaceutical therapeutic approaches and mainly highlighted the cutting-edge treatments for PD including gene- and stem cell-based therapies, targeted delivery of neurotrophic factors, and brain stimulation techniques such as Transcranial Magnetic Stimulation (TMS), transcranial Direct Current Stimulation (tDCS), and Deep Brain Stimulation (DBS). The review covered various gene therapy strategies including Adeno-Associated Virus-Glutamic Acid Decarboxylase (AAV-GAD), AAV–Aromatic L-Amino Acid Decarboxylase (AAV-AADC), Lenti-AADC/Tyrosine Hydroxylase/Guanosine Triphosphate- Cyclohydrolase I (Lenti-AADC/TH/GTP-CH1), AAV–Neurturin (AAV-NRTN), α-Synuclein silencing, and PRKN gene delivery. Also, the advantages, disadvantages, and the results of trials of these methods were discussed. Finally, reasons for the failure of PD treatment were described, with the hopes separated from hypes.
Keywords: PRKN gene delivery, α-Synuclein silencing, tDCS, DBS, Cell therapy, AAV-GAD.
Current Gene Therapy
Title:Cellular, Molecular and Non-Pharmacological Therapeutic Advances for the Treatment of Parkinson's Disease: Separating Hope from Hype
Volume: 18 Issue: 4
Author(s): Mehdi Ghamgosha, Ali Mohammad Latifi, Gholam Hossein Meftahi and Alireza Mohammadi*
Affiliation:
- Neuroscience Research Center, Baqiyatallah University of Medical Sciences, Tehran,Iran
Keywords: PRKN gene delivery, α-Synuclein silencing, tDCS, DBS, Cell therapy, AAV-GAD.
Abstract: Parkinson’s Disease (PD) is a frustrating condition characterized by motor and nonmotor deficits majorly caused by the loss of dopaminergic cells in the Substantia Nigra pars compacta (SNc) and destruction of the nigrostriatal pathway. Despite the very respectable advances in cutting-edge approaches for the treatment of PD, there exist numerous challenges that have incapacitated the definitive treatment of this disease. This review emphasized the development of various non-pharmaceutical therapeutic approaches and mainly highlighted the cutting-edge treatments for PD including gene- and stem cell-based therapies, targeted delivery of neurotrophic factors, and brain stimulation techniques such as Transcranial Magnetic Stimulation (TMS), transcranial Direct Current Stimulation (tDCS), and Deep Brain Stimulation (DBS). The review covered various gene therapy strategies including Adeno-Associated Virus-Glutamic Acid Decarboxylase (AAV-GAD), AAV–Aromatic L-Amino Acid Decarboxylase (AAV-AADC), Lenti-AADC/Tyrosine Hydroxylase/Guanosine Triphosphate- Cyclohydrolase I (Lenti-AADC/TH/GTP-CH1), AAV–Neurturin (AAV-NRTN), α-Synuclein silencing, and PRKN gene delivery. Also, the advantages, disadvantages, and the results of trials of these methods were discussed. Finally, reasons for the failure of PD treatment were described, with the hopes separated from hypes.
Export Options
About this article
Cite this article as:
Ghamgosha Mehdi , Latifi Mohammad Ali , Meftahi Hossein Gholam and Mohammadi Alireza *, Cellular, Molecular and Non-Pharmacological Therapeutic Advances for the Treatment of Parkinson's Disease: Separating Hope from Hype, Current Gene Therapy 2018; 18 (4) . https://dx.doi.org/10.2174/1566523218666180910163401
DOI https://dx.doi.org/10.2174/1566523218666180910163401 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patents of Pentoxifylline Administration on Some Diseases and Chronic Wounds
Recent Patents on Regenerative Medicine Photodynamic Therapy: The Light Treatment for Cutaneous Non- Melanoma Malignancies
Current Cancer Therapy Reviews Critical Congenital Heart Disease in Neonates: A Review Article
Current Pediatric Reviews Pulmonary Vasodilators in the Management of Low Cardiac Output Syndrome After Pediatric Cardiac Surgery
Current Vascular Pharmacology Engineered Inorganic/Organic-Core/Shell Magnetic Fe<sub>x</sub>O<sub>y</sub> Nanoparticles with Oleic Acid and/or Oleylamine As Capping Agents
Current Pharmaceutical Design Herbal Natural Products As a Source of Monoamine Oxidase Inhibitors: A Review
Current Topics in Medicinal Chemistry Current Developments in the Synthesis and Biological Activity of Aza-C-Nucleosides:Immucillins and Related Compounds
Current Medicinal Chemistry The Cytotoxicity of Titanocene Y Against CAKI-1 Cells: An In Vitro Formulation Study
Letters in Drug Design & Discovery Effects of Obesity on Vascular Potassium Channels
Current Vascular Pharmacology Role of Heme Oxygenase-1 in Cardiovascular Function
Current Pharmaceutical Design Pulmonary Embolism and Pregnancy
Current Women`s Health Reviews Baicalein-Phospholipid Complex: A Novel Drug Delivery Technology for Phytotherapeutics
Current Drug Discovery Technologies Hydrolyzates of Silkworm Pupae (Bombyx Mori) Protein is a New Source of Angiotensin I-Converting Enzyme Inhibitory Peptides(ACEIP)
Current Pharmaceutical Biotechnology Chemistry and Biology of Cyperus scariosus: An Overview
Current Chemical Biology ACE2-Ang-(1-7)-Mas Axis in Brain: A Potential Target for Prevention and Treatment of Ischemic Stroke
Current Neuropharmacology Biologics and the Cardiovascular System: A Double-Edged Sword
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry High Sensitivity Troponin in Cardiovascular Disease. Is There More Than a Marker of Myocardial Death?
Current Topics in Medicinal Chemistry Cardiovascular Pharmacogenetics of Antihypertensive and Lipid- Lowering Therapies
Current Molecular Medicine Classical Neurotransmitters and Neuropeptides Involved in Schizophrenia: How to Choose the Appropriate Antipsychotic Drug?
Current Drug Therapy Ghrelin, A Novel Peptide Hormone in the Regulation of Energy Balance and Cardiovascular Function
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery